Fact CheckerSign in

NCT02924701Active, not recruiting

sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis

Macrophage Activation Marker sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis

Source: ClinicalTrials.gov · Last updated 12 Aug 2022

Brief summary (registry, in English)

Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR correlate with disease severity in patients with PBC, and whether sCD163 and sMR can predict short term disease progression, changes in quality of life and death in these patients.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
168 (actual)
First submitted
4 Oct 2016
Start date
Sept 2016
Primary completion date
Jan 2031
Lead sponsor
University of Aarhus
NCT number
NCT02924701

What you commit to

  • Study type: Observational
  • Participants enrolled: 168
  • From Sept 2016 to the primary completion date, Jan 2031
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Planned liver transplantation within 6 months

Other illness

  • Cirrhosis from other causes (except autoimmune hepatitis)
  • Liver cancer

Other

  • Patient under 18 years
  • Expected lifetime below 6 months

Who the study is looking for

  • Diagnosed with primary biliary cholangitis

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
Coordinator of this site? Confirm its status
Aarhus CDenmarkUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.